Dementia Research Today is a free monthly online journal that collates and summarizes the latest research about Dementia, including details on symptoms, alzheimers, senile dementia, causes.

Volume 8 (2011), Issue 5 (May)

1. Effects of distraction and pictorial illustration on memory for countries in older adults with probable Alzheimer's disease.
   Exp Aging Res, 37(3): 293-309. [Abstract] [Full-text]
2. The nature and scope of stressful spousal caregiving relationships.
   J Fam Nurs, 17(2): 224-40. [Abstract] [Full-text]
3. Alzheimer's pathogenesis: is there neuron-to-neuron propagation?
   Acta Neuropathol, 121(5): 589-95. [Abstract] [Full-text]
4. Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies.
   Acta Neuropathol, 121(5): 571-87. [Abstract] [Full-text]
5. Homocysteine effects on brain volumes mapped in 732 elderly individuals.
   Neuroreport, 22(8): 391-5. [Abstract] [Full-text]
6. Synthesis and evaluation of heterobivalent tacrine derivatives as potential multi-functional anti-Alzheimer agents.
   Eur J Med Chem, 46(6): 2609-16. [Abstract] [Full-text]
7. Current understanding of HIV-associated neurocognitive disorders pathogenesis.
   Curr Opin Neurol, 24(3): 275-83. [Abstract] [Full-text]
8. Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
   Eur J Med Chem, 46(6): 2170-84. [Abstract] [Full-text]
9. 2-Arylimidazo[2,1-b]benzothiazoles: a new family of amyloid binding agents with potential for PET and SPECT imaging of Alzheimer's brain.
   Bioorg Med Chem Lett, 21(10): 2966-8. [Abstract] [Full-text]
10. Hippocampal and amygdalar volume changes in elderly patients with Alzheimer's disease and schizophrenia.
    Psychiatry Res, 192(2): 77-83. [Abstract] [Full-text]
11. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia.
    J Biol Chem, 286(18): 16101-8. [Abstract] [Full-text]
12. N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
    Eur J Med Chem, 46(6): 2224-35. [Abstract] [Full-text]
13. Multi-template tensor-based morphometry: application to analysis of Alzheimer's disease.
    Neuroimage, 56(3): 1134-44. [Abstract] [Full-text]
14. Evidence for functional specialization of hippocampal subfields detected by MR subfield volumetry on high resolution images at 4 T.
    Neuroimage, 56(3): 851-7. [Abstract] [Full-text]
15. Assessment of the efficacy of solutes from extremophiles on protein aggregation in cell models of Huntington's and Parkinson's diseases.
    Neurochem Res, 36(6): 1005-11. [Abstract] [Full-text]
16. Biomarkers of Alzheimer's disease in the cerebrospinal fluid of Spanish patients with mild cognitive impairment.
    Neurochem Res, 36(6): 986-93. [Abstract] [Full-text]
17. The structural neuroanatomy of music emotion recognition: evidence from frontotemporal lobar degeneration.
    Neuroimage, 56(3): 1814-21. [Abstract] [Full-text]
18. Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI.
    Neuroimage, 56(3): 890-906. [Abstract] [Full-text]
19. Quantitative in vivo measurement of early axonal transport deficits in a triple transgenic mouse model of Alzheimer's disease using manganese-enhanced MRI.
    Neuroimage, 56(3): 1286-92. [Abstract] [Full-text]
20. Age and disease related changes in the translocator protein (TSPO) system in the human brain: positron emission tomography measurements with [11C]vinpocetine.
    Neuroimage, 56(3): 1111-21. [Abstract] [Full-text]
21. Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model.
    Neuroimage, 56(3): 1027-34. [Abstract] [Full-text]
22. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.
    Acta Neuropathol, 121(5): 597-609. [Abstract] [Full-text]
23. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease.
    FASEB J, 25(5): 1585-95. [Abstract] [Full-text]
24. Granular expression of prolyl-peptidyl isomerase PIN1 is a constant and specific feature of Alzheimer's disease pathology and is independent of tau, Aβ and TDP-43 pathology.
    Acta Neuropathol, 121(5): 635-49. [Abstract] [Full-text]
25. Shunt surgery in patients with hydrocephalus and white matter changes.
    J Neurosurg, 114(5): 1432-8. [Abstract] [Full-text]
26. Brodmann area 12: an historical puzzle relevant to FTLD.
    Neurology, 76(18): 1596-9. [Abstract] [Full-text]
27. Midlife overweight and obesity increase late-life dementia risk: a population-based twin study.
    Neurology, 76(18): 1568-74. [Abstract] [Full-text]
28. New wine in old bottle: late-life psychosis.
    Psychiatr Clin North Am, 34(2): 295-318, vii. [Abstract] [Full-text]
29. Epidemiology, assessment, and treatment of dementia.
    Psychiatr Clin North Am, 34(2): 275-94, vii. [Abstract] [Full-text]
30. Dexamethasone potentiated Aβ-induced learning and memory impairment in rats.
    Neurol Res, 33(4): 371-80. [Abstract] [Full-text]
31. Granulocyte-colony stimulating factor protects memory impairment in the senescence-accelerated mouse (SAM)-P10.
    Neurol Res, 33(4): 354-9. [Abstract] [Full-text]
32. Does dementia increase risk of thrombolysis?: a case-control study.
    Neurology, 76(18): 1575-80. [Abstract] [Full-text]
33. Association analysis of GSK3B and MAPT polymorphisms with Alzheimer's disease in Han Chinese.
    Brain Res, 1391: 147-53. [Abstract] [Full-text]
34. Focal and nonfocal prospective memory performance in very mild dementia: a signature decline.
    Neuropsychology, 25(3): 387-96. [Abstract] [Full-text]
35. Attentional control in normal aging and Alzheimer's disease.
    Neuropsychology, 25(3): 353-67. [Abstract] [Full-text]
36. Abnormal error-related antisaccade activation in premanifest and early manifest Huntington disease.
    Neuropsychology, 25(3): 306-18. [Abstract] [Full-text]
37. Management of person with dementia with aggressive and violent behaviour: a systematic literature review.
    Int J Older People Nurs, 6(2): 153-62. [Abstract] [Full-text]
38. Korean nurses' attitudes towards older people with dementia in acute care settings.
    Int J Older People Nurs, 6(2): 143-52. [Abstract] [Full-text]
39. Insights gained through Marte Meo counselling: experiences of nurses in dementia specific care units.
    Int J Older People Nurs, 6(2): 123-32. [Abstract] [Full-text]
40. Perceptions and implications of violence from care home residents with dementia: a review and commentary.
    Int J Older People Nurs, 6(2): 110-22. [Abstract] [Full-text]
41. Experiences of relocation in dementia care from the perspective of six care workers.
    Int J Older People Nurs, 6(2): 93-101. [Abstract] [Full-text]
42. Diet and Alzheimer's disease risk factors or prevention: the current evidence.
    Expert Rev Neurother, 11(5): 677-708. [Abstract] [Full-text]
43. Loss of motor function in preclinical Alzheimer's disease.
    Expert Rev Neurother, 11(5): 665-76. [Abstract] [Full-text]
44. Management of suspected Alzheimer's disease patients by specialist physicians at the first visit in Spain: First Consultation Study.
    Expert Rev Neurother, 11(5): 657-63. [Abstract] [Full-text]
45. Life-course socioeconomic position and incidence of dementia and cognitive impairment without dementia in older Mexican Americans: results from the Sacramento area Latino study on aging.
    Am J Epidemiol, 173(10): 1148-58. [Abstract] [Full-text]
46. Mechanisms of neural and behavioral dysfunction in Alzheimer's disease.
    Mol Neurobiol, 43(3): 163-79. [Abstract] [Full-text]
47. Mitogen-activated protein kinase p38 in HIV infection and associated brain injury.
    J Neuroimmune Pharmacol, 6(2): 202-15. [Abstract] [Full-text]
48. Modeling trajectories and transitions: results from the New York University caregiver intervention.
    Nurs Res, 60(3): S28-37. [Abstract] [Full-text]
49. BACE1 activity is modulated by cell-associated sphingosine-1-phosphate.
    J Neurosci, 31(18): 6850-7. [Abstract] [Full-text]
50. Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults.
    J Neurosci, 31(18): 6764-70. [Abstract] [Full-text]
51. Development of a short-form assessment for detection of subtle activity limitations: can use of everyday technology distinguish between MCI and Alzheimer's disease?
    Expert Rev Neurother, 11(5): 647-55. [Abstract] [Full-text]
52. Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease.
    Acta Pharmacol Sin, 32(5): 545-51. [Abstract] [Full-text]
53. Identity matching in a patient with Alzheimer's disease.
    Am J Alzheimers Dis Other Demen, 26(3): 247-53. [Abstract] [Full-text]
54. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence.
    Am J Alzheimers Dis Other Demen, 26(3): 169-83. [Abstract] [Full-text]
55. Guiding research and practice: a conceptual model for aerobic exercise training in Alzheimer's disease.
    Am J Alzheimers Dis Other Demen, 26(3): 184-94. [Abstract] [Full-text]
56. Beneficial care approaches in specialized daycare units for persons with dementia.
    Am J Alzheimers Dis Other Demen, 26(3): 240-6. [Abstract] [Full-text]
57. Comparison of the memory performance index with standard neuropsychological measures of cognition.
    Am J Alzheimers Dis Other Demen, 26(3): 235-9. [Abstract] [Full-text]
58. Determinants of the desire to institutionalize in Alzheimer's caregivers.
    Am J Alzheimers Dis Other Demen, 26(3): 205-11. [Abstract] [Full-text]
59. The Memory Club: Providing support to persons with early-stage dementia and their care partners.
    Am J Alzheimers Dis Other Demen, 26(3): 218-26. [Abstract] [Full-text]
60. Difficult diagnoses: Family caregivers' experiences during and following the diagnostic process for dementia.
    Am J Alzheimers Dis Other Demen, 26(3): 212-7. [Abstract] [Full-text]
61. Exploring the reasons urban and rural-dwelling older adults participate in memory research.
    Am J Alzheimers Dis Other Demen, 26(3): 227-34. [Abstract] [Full-text]
62. Use of services by community-dwelling patients with dementia: a systematic review.
    Am J Alzheimers Dis Other Demen, 26(3): 195-204. [Abstract] [Full-text]
63. Quantitative and qualitative analyses of the clock drawing test in mild cognitive impairment and Alzheimer disease: evaluation of a modified scoring system.
    J Geriatr Psychiatry Neurol, 24(2): 108-18. [Abstract] [Full-text]
64. Different associations of periventricular and deep white matter lesions with cognition, neuropsychiatric symptoms, and daily activities in dementia.
    J Geriatr Psychiatry Neurol, 24(2): 84-90. [Abstract] [Full-text]
65. Genetics of Alzheimer's disease: an insight into presenilins and apolipoprotein E instigated neurodegeneration.
    Int J Neurosci, 121(5): 229-36. [Abstract] [Full-text]
66. Solanezumab for Alzheimer's disease.
    Expert Opin Biol Ther, 11(6): 787-98. [Abstract] [Full-text]
67. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.
    Expert Opin Biol Ther, 11(6): 679-86. [Abstract] [Full-text]
68. ABCB1 genotype and CSF beta-amyloid in Alzheimer disease.
    J Geriatr Psychiatry Neurol, 24(2): 63-6. [Abstract] [Full-text]
69. Development of a novel FMRI compatible visual perception prototype battery to test older people with and without dementia.
    J Geriatr Psychiatry Neurol, 24(2): 73-83. [Abstract] [Full-text]
70. Simultaneous determination of catecholamines and their metabolites related to Alzheimer's disease in human urine.
    J Sep Sci, 34(10): 1198-204. [Abstract] [Full-text]
71. Validity and responsiveness to change of clinically derived MDS scales in Alzheimer disease outcomes research.
    J Geriatr Psychiatry Neurol, 24(2): 67-72. [Abstract] [Full-text]
72. The effect of empiric antibiotic therapy on mortality in debilitated patients with dementia.
    Eur J Clin Microbiol Infect Dis, 30(6): 813-8. [Abstract] [Full-text]
73. Interactions of Npc1 and amyloid accumulation/deposition in the APP/PS1 mouse model of Alzheimer's.
    J Appl Genet, 52(2): 213-8. [Abstract] [Full-text]
74. Underestimation of the expression of cellular prion protein on human red blood cells.
    Transfusion, 51(5): 1012-21. [Abstract] [Full-text]
75. Apolipoprotein E4 frequencies in a Japanese population with Alzheimer's disease and dementia with Lewy bodies.
    PLoS One, 6(4): e18569. [Abstract] [Full-text]
76. Presenilin-1 mutation Alzheimer's disease: a genetic epilepsy syndrome?
    Epilepsy Behav, 21(1): 20-2. [Abstract] [Full-text]
77. A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease.
    Neurosci Lett, 496(1): 40-2. [Abstract] [Full-text]
78. Rapid eye movement sleep atonia in patients with cognitive impairment.
    J Neurol Sci, 305(1): 34-7. [Abstract] [Full-text]
79. Increased plasma levels of lipocalin 2 in mild cognitive impairment.
    J Neurol Sci, 305(1): 28-33. [Abstract] [Full-text]
80. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
    J Neurol Sci, 305(1): 92-6. [Abstract] [Full-text]
81. Autonomic dysfunction in neurodegenerative dementias.
    J Neurol Sci, 305(1): 22-7. [Abstract] [Full-text]
82. Behavioral stress causes mitochondrial dysfunction via ABAD up-regulation and aggravates plaque pathology in the brain of a mouse model of Alzheimer disease.
    Free Radic Biol Med, 50(11): 1526-35. [Abstract] [Full-text]
83. Endoplasmic reticulum stress activates autophagy but not the proteasome in neuronal cells: implications for Alzheimer's disease.
    Cell Death Differ, 18(6): 1071-81. [Abstract] [Full-text]
84. Diagnosing variant Creutzfeldt-Jakob disease: a retrospective analysis of the first 150 cases in the UK.
    J Neurol Neurosurg Psychiatry, 82(6): 646-51. [Abstract] [Full-text]
85. Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'.
    J Pathol, 224(2): 147-52. [Abstract] [Full-text]
86. Fractal analysis reveals reduced complexity of retinal vessels in CADASIL.
    PLoS One, 6(4): e19150. [Abstract] [Full-text]
87. Huntington chorea presenting with motor neuron disease.
    Arch Neurol, 68(5): 650-2. [Abstract] [Full-text]
88. Mild cognitive impairment, dementia, and their subtypes in oldest old women.
    Arch Neurol, 68(5): 631-6. [Abstract] [Full-text]
89. The APOE gene locus in frontotemporal dementia and primary progressive aphasia.
    Arch Neurol, 68(5): 622-8. [Abstract] [Full-text]
90. Telephone-based identification of mild cognitive impairment and dementia in a multicultural cohort.
    Arch Neurol, 68(5): 607-14. [Abstract] [Full-text]
91. Test-retest reliability of memory task functional magnetic resonance imaging in Alzheimer disease clinical trials.
    Arch Neurol, 68(5): 599-606. [Abstract] [Full-text]
92. An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice.
    Neuron, 70(3): 427-40. [Abstract] [Full-text]
93. Alternative drug therapies for dementia.
    J Psychosoc Nurs Ment Health Serv, 49(5): 17-20. [Abstract] [Full-text]
94. Mutations that replace aromatic side chains promote aggregation of the Alzheimer's Aβ peptide.
    Biochemistry, 50(19): 4058-67. [Abstract] [Full-text]
95. Is there a specific pattern of attention deficit in mild cognitive impairment with subcortical vascular features? Evidence from the Attention Network Test.
    Dement Geriatr Cogn Disord, 31(4): 268-75. [Abstract] [Full-text]
96. Conceptual framework for cognitive function enhancement in people with dementia.
    J Clin Nurs, 20(11): 1533-41. [Abstract] [Full-text]
97. Prevalence and pathology of dementia with Lewy bodies in the oldest old: a comparison with other dementing disorders.
    Dement Geriatr Cogn Disord, 31(4): 309-16. [Abstract] [Full-text]
98. Could iron accumulation be an etiology of the white matter change in Alzheimer's disease: using phase imaging to detect white matter iron deposition based on diffusion tensor imaging.
    Dement Geriatr Cogn Disord, 31(4): 300-8. [Abstract] [Full-text]
99. Cognitive impairment in mild general paresis of the insane: AD-like pattern.
    Dement Geriatr Cogn Disord, 31(4): 284-90. [Abstract] [Full-text]
100. Minimal atrophy of the entorhinal cortex and hippocampus: progression of cognitive impairment.
     Dement Geriatr Cogn Disord, 31(4): 276-83. [Abstract] [Full-text]
101. Animal-assisted therapy for clients with dementia.
     J Gerontol Nurs, 37(5): 10-4. [Abstract] [Full-text]
102. KUD--a scale for clinical evaluation of moderate-to-severe dementia.
     J Clin Nurs, 20(11): 1542-52. [Abstract] [Full-text]
103. Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease.
     Hum Mol Genet, 20(11): 2225-37. [Abstract] [Full-text]
104. Parkin mediates beclin-dependent autophagic clearance of defective mitochondria and ubiquitinated Abeta in AD models.
     Hum Mol Genet, 20(11): 2091-102. [Abstract] [Full-text]
105. Parallel high throughput neuronal toxicity assays demonstrate uncoupling between loss of mitochondrial membrane potential and neuronal damage in a model of HIV-induced neurodegeneration.
     Neurosci Res, 70(2): 220-9. [Abstract] [Full-text]
106. Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk.
     Genet Med, 13(5): 409-14. [Abstract] [Full-text]
107. Functional transitions of nursing home residents with middle-stage dementia.
     J Gerontol Nurs, 37(5): 50-9. [Abstract] [Full-text]
108. Association of lung function with cognitive decline and dementia: the Atherosclerosis Risk in Communities (ARIC) Study.
     Eur J Neurol, 18(6): 888-98. [Abstract] [Full-text]
109. The impact of cerebral amyloid angiopathy on the occurrence of cerebrovascular lesions in demented patients with Alzheimer features: a neuropathological study.
     Eur J Neurol, 18(6): 913-8. [Abstract] [Full-text]
110. Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels.
     Arch Neurol, 68(5): 581-6. [Abstract] [Full-text]
111. Medicare expenditures among nursing home residents with advanced dementia.
     Arch Intern Med, 171(9): 824-30. [Abstract] [Full-text]
112. EEG low-resolution brain electromagnetic tomography (LORETA) in Huntington's disease.
     J Neurol, 258(5): 840-54. [Abstract] [Full-text]
113. Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases.
     Eur J Neurol, 18(6): 865-71. [Abstract] [Full-text]
114. Dimebolin in dementia.
     CNS Neurosci Ther, 17(3): 199-205. [Abstract] [Full-text]
115. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.
     PLoS One, 6(4): e19338. [Abstract] [Full-text]
116. Characterization of AβpN3 deposition in the brains of dogs of various ages and other animal species.
     Amyloid, 18(2): 63-71. [Abstract] [Full-text]
117. Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease.
     Vaccine, 29(23): 4043-50. [Abstract] [Full-text]
118. Are elderly dependency ratios associated with general population suicide rates?
     Int J Soc Psychiatry, 57(3): 277-83. [Abstract] [Full-text]
119. Fronto-temporal lobar degeneration: neuropathology in 60 cases.
     J Neural Transm, 118(5): 753-64. [Abstract] [Full-text]
120. Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study.
     J Neural Transm, 118(5): 765-72. [Abstract] [Full-text]
121. Striatal β-amyloid in dementia with Lewy bodies but not Parkinson's disease.
     J Neural Transm, 118(5): 713-9. [Abstract] [Full-text]
122. Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.
     J Neural Transm, 118(5): 747-52. [Abstract] [Full-text]
123. Prospective study on association between plasma amyloid beta-42 and atherosclerotic risk factors.
     J Neural Transm, 118(5): 663-72. [Abstract] [Full-text]
124. Polyneuropathy and dementia in old age: common inflammatory and vascular parameters.
     J Neural Transm, 118(5): 721-5. [Abstract] [Full-text]
125. Different CSF β-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease.
     J Neural Transm, 118(5): 691-7. [Abstract] [Full-text]
126. Amyloid-β protein modulates the perivascular clearance of neuronal apolipoprotein E in mouse models of Alzheimer's disease.
     J Neural Transm, 118(5): 699-712. [Abstract] [Full-text]
127. Recruitment of Chinese American elders into dementia research: the UCSF ADRC experience.
     Gerontologist, 51: S125-33. [Abstract] [Full-text]
128. Stress, exercise, and Alzheimer's disease: a neurovascular pathway.
     Med Hypotheses, 76(6): 847-54. [Abstract] [Full-text]
129. Cerebral lobar microhemorrhages detection by high magnetic field susceptibility weighted image: a potential diagnostic neuroimage technique of Alzheimer's disease.
     Med Hypotheses, 76(6): 840-2. [Abstract] [Full-text]
130. Interaction between 24-hydroxycholesterol, oxidative stress, and amyloid-β in amplifying neuronal damage in Alzheimer's disease: three partners in crime.
     Aging Cell, 10(3): 403-17. [Abstract] [Full-text]
131. Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice.
     Aging Cell, 10(3): 418-28. [Abstract] [Full-text]
132. Dendritic and spinal pathology in the acoustic cortex in Alzheimer's disease: morphological estimation in Golgi technique and electron microscopy.
     Acta Otolaryngol, 131(6): 610-2. [Abstract] [Full-text]
133. An interdisciplinary outreach model of African American recruitment for Alzheimer's disease research.
     Gerontologist, 51: S134-41. [Abstract] [Full-text]
134. The cholinergic system in aging and neuronal degeneration.
     Behav Brain Res, 221(2): 555-63. [Abstract] [Full-text]
135. The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine.
     Behav Brain Res, 221(2): 594-603. [Abstract] [Full-text]
136. Occupational performance and awareness of disability in mild cognitive impairment or dementia.
     Scand J Occup Ther, 18(2): 133-42. [Abstract] [Full-text]
137. The cerebrovascular role of the cholinergic neural system in Alzheimer's disease.
     Behav Brain Res, 221(2): 537-42. [Abstract] [Full-text]
138. The history of the cholinergic hypothesis.
     Behav Brain Res, 221(2): 334-40. [Abstract] [Full-text]
139. Olfactory and visuospatial learning and memory performance in two strains of Alzheimer's disease model mice--a longitudinal study.
     PLoS One, 6(5): e19567. [Abstract] [Full-text]
140. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
     PLoS One, 6(5): e19264. [Abstract] [Full-text]
141. Does caring for a spouse with dementia promote cognitive decline? A hypothesis and proposed mechanisms.
     J Am Geriatr Soc, 59(5): 900-8. [Abstract] [Full-text]
142. Incidence of and risk factors for dementia in the Ibadan study of aging.
     J Am Geriatr Soc, 59(5): 869-74. [Abstract] [Full-text]
143. Decision-making and outcomes of feeding tube insertion: a five-state study.
     J Am Geriatr Soc, 59(5): 881-6. [Abstract] [Full-text]
144. Sir2 is induced by oxidative stress in a yeast model of Huntington disease and its activation reduces protein aggregation.
     Arch Biochem Biophys, 510(1): 27-34. [Abstract] [Full-text]
145. Day care for dementia patients from a family caregiver's point of view: a questionnaire study on expected quality and predictors of utilisation - Part II.
     BMC Health Serv Res, 11: 76. [Abstract] [Full-text]
146. The world of dementia beyond 2020.
     J Am Geriatr Soc, 59(5): 923-7. [Abstract] [Full-text]
147. Insight into amyloid structure using chemical probes.
     Chem Biol Drug Des, 77(6): 399-411. [Abstract] [Full-text]
148. Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein.
     J Biol Chem, 286(20): 18320-30. [Abstract] [Full-text]
149. Spatial learning and memory impairment and increased locomotion in a transgenic amyloid precursor protein mouse model of Alzheimer's disease.
     Behav Brain Res, 222(1): 169-75. [Abstract] [Full-text]
150. A detailed analysis of the early context extinction deficits seen in APPswe/PS1dE9 female mice and their relevance to preclinical Alzheimer's disease.
     Behav Brain Res, 222(1): 89-97. [Abstract] [Full-text]
151. Mitotic spindle: focus on the function of huntingtin.
     Int J Biochem Cell Biol, 43(6): 852-6. [Abstract] [Full-text]
152. Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function.
     Mol Biosyst, 7(6): 1822-7. [Abstract] [Full-text]
153. Aluminum, copper, iron and zinc differentially alter amyloid-Aβ(1-42) aggregation and toxicity.
     Int J Biochem Cell Biol, 43(6): 877-85. [Abstract] [Full-text]
154. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease.
     Eur J Nucl Med Mol Imaging, 38(6): 1104-19. [Abstract] [Full-text]
155. Applying the WHO ICF framework to communication assessment and goal setting in Huntington's disease: a case discussion.
     J Commun Disord, 44(3): 261-75. [Abstract] [Full-text]
156. Verb production during action naming in semantic dementia.
     J Commun Disord, 44(3): 379-91. [Abstract] [Full-text]
157. Targeting the hematopoietic system for the treatment of Alzheimer's disease.
     Brain Behav Immun, 25: S71-9. [Abstract] [Full-text]
158. Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease.
     Neurology, 76(20): 1720-5. [Abstract] [Full-text]
159. Risk of Alzheimer's disease incidence attributable to vascular disease in the population.
     Alzheimers Dement, 7(3): 356-60. [Abstract] [Full-text]
160. Assessment of cognition in mild cognitive impairment: a comparative study.
     Alzheimers Dement, 7(3): 338-55. [Abstract] [Full-text]
161. Commentary on "Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." A Canadian perspective.
     Alzheimers Dement, 7(3): 330-2. [Abstract] [Full-text]
162. Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients.
     Alzheimers Dement, 7(3): 318-27. [Abstract] [Full-text]
163. Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease.
     Alzheimers Dement, 7(3): 300-8. [Abstract] [Full-text]
164. Language and behavior domains enhance the value of the clinical dementia rating scale.
     Alzheimers Dement, 7(3): 293-9. [Abstract] [Full-text]
165. Biomarkers in Alzheimer's disease drug development.
     Alzheimers Dement, 7(3): e13-44. [Abstract] [Full-text]
166. Alzheimer's disease management guideline: update 2008.
     Alzheimers Dement, 7(3): e51-9. [Abstract] [Full-text]
167. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
     Alzheimers Dement, 7(3): 263-9. [Abstract] [Full-text]
168. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
     Alzheimers Dement, 7(3): 270-9. [Abstract] [Full-text]
169. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
     Alzheimers Dement, 7(3): 280-92. [Abstract] [Full-text]
170. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
     Alzheimers Dement, 7(3): 257-62. [Abstract] [Full-text]
171. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
     Behav Brain Res, 222(2): 342-50. [Abstract] [Full-text]
172. Regional cerebral blood flow and aberrant motor behaviour in Alzheimer's disease.
     Behav Brain Res, 222(2): 375-9. [Abstract] [Full-text]
173. Interfering effect and mechanism of neuregulin on experimental dementia model in rats.
     Behav Brain Res, 222(2): 321-5. [Abstract] [Full-text]
174. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias.
     Neurology, 76(20): 1711-9. [Abstract] [Full-text]
175. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease.
     Neurobiol Dis, 43(1): 257-65. [Abstract] [Full-text]
176. Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay.
     Neurobiol Dis, 43(1): 248-56. [Abstract] [Full-text]
177. Decreased expression of GGA3 protein in Alzheimer's disease frontal cortex and increased co-distribution of BACE with the amyloid precursor protein.
     Neurobiol Dis, 43(1): 176-83. [Abstract] [Full-text]
178. Effects of attention on dichotic listening in elderly and patients with dementia of the Alzheimer type.
     Brain Cogn, 76(2): 286-93. [Abstract] [Full-text]
179. Rescue of neurons from undergoing hallmark tau-induced Alzheimer's disease cell pathologies by the antimitotic drug paclitaxel.
     Neurobiol Dis, 43(1): 163-75. [Abstract] [Full-text]
180. Exemplary care as a mediator of the effects of caregiver subjective appraisal and emotional outcomes.
     Gerontologist, 51(3): 332-42. [Abstract] [Full-text]
181. Autophagy failure in Alzheimer's disease--locating the primary defect.
     Neurobiol Dis, 43(1): 38-45. [Abstract] [Full-text]
182. Factors associated with problematic vocalizations in nursing home residents with dementia.
     Gerontologist, 51(3): 389-405. [Abstract] [Full-text]
183. Proteasomal dysfunction in aging and Huntington disease.
     Neurobiol Dis, 43(1): 4-8. [Abstract] [Full-text]
184. Depletion of Beclin-1 due to proteolytic cleavage by caspases in the Alzheimer's disease brain.
     Neurobiol Dis, 43(1): 68-78. [Abstract] [Full-text]
185. Metabolomic changes in autopsy-confirmed Alzheimer's disease.
     Alzheimers Dement, 7(3): 309-17. [Abstract] [Full-text]
186. Current strategies in the discovery of small-molecule biomarkers for Alzheimer's disease.
     Bioanalysis, 3(10): 1121-42. [Abstract] [Full-text]
187. Improved social interaction and increased anterior cingulate metabolism after group reminiscence with reality orientation approach for vascular dementia.
     Psychiatry Res, 192(3): 183-7. [Abstract] [Full-text]
188. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease.
     Mol Pharmacol, 79(6): 964-73. [Abstract] [Full-text]
189. Role of deferoxamine on enzymatic stress markers in an animal model of Alzheimer's disease after chronic aluminum exposure.
     Biol Trace Elem Res, 141(1): 232-45. [Abstract] [Full-text]
190. Implant-supported overdenture in an elderly patient with Huntington's disease.
     Gerodontology, 28(2): 157-60. [Abstract] [Full-text]
191. Low-density lipoprotein receptor-related protein is decreased in optic neuropathy of Alzheimer disease.
     J Neuroophthalmol, 31(2): 139-46. [Abstract] [Full-text]
192. Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein.
     J Neurosci, 31(20): 7259-63. [Abstract] [Full-text]
193. An intervention to reduce care-resistant behavior in persons with dementia during oral hygiene: a pilot study.
     Spec Care Dentist, 31(3): 77-87. [Abstract] [Full-text]
194. Clinical factors related to brain structure in HIV: the CHARTER study.
     J Neurovirol, 17(3): 248-57. [Abstract] [Full-text]
195. The mechanism for heme to prevent Aβ(1-40) aggregation and its cytotoxicity.
     J Biol Inorg Chem, 16(5): 809-16. [Abstract] [Full-text]
196. Human immunodeficiency virus type 1 clade B and C gp120 differentially induce neurotoxin arachidonic acid in human astrocytes: implications for neuroAIDS.
     J Neurovirol, 17(3): 230-8. [Abstract] [Full-text]
197. Physicians' and nurses' perceived usefulness and acceptability of a family information booklet about comfort care in advanced dementia.
     J Palliat Med, 14(5): 614-22. [Abstract] [Full-text]
198. Hippocampal sclerosis in advanced age: clinical and pathological features.
     Brain, 134: 1506-18. [Abstract] [Full-text]
199. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
     Brain, 134: 1493-505. [Abstract] [Full-text]
200. Quality of life of residents with dementia in long-term care settings in the Netherlands and Belgium: design of a longitudinal comparative study in traditional nursing homes and small-scale living facilities.
     BMC Geriatr, 11: 20. [Abstract] [Full-text]
201. Site-specific hyperphosphorylation of pRb in HIV-induced neurotoxicity.
     Mol Cell Neurosci, 47(2): 154-65. [Abstract] [Full-text]
202. Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors.
     Anal Bioanal Chem, 400(7): 1979-96. [Abstract] [Full-text]
203. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition.
     Brain, 134: 1479-92. [Abstract] [Full-text]
204. Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer's disease.
     Neurobiol Aging, 32(6): 1079-89. [Abstract] [Full-text]
205. Early inflammation and immune response mRNAs in the brain of AD11 anti-NGF mice.
     Neurobiol Aging, 32(6): 1007-22. [Abstract] [Full-text]
206. Sex-dependent changes in social behaviors in motor pre-symptomatic R6/1 mice.
     PLoS One, 6(5): e19965. [Abstract] [Full-text]
207. Psychoses as the presenting manifestation of Creutzfeldt-Jakob disease in an elderly male.
     Gen Hosp Psychiatry, 33(3): 302.e7-9. [Abstract] [Full-text]
208. Development of biomarkers for Huntington's disease.
     Lancet Neurol, 10(6): 573-90. [Abstract] [Full-text]
209. Occupational therapy practice in Australia with people with dementia: a profile in need of change.
     Aust Occup Ther J, 58(3): 155-63. [Abstract] [Full-text]
210. Impairment of the activity of the plasma membrane Ca²⁺-ATPase in Alzheimer's disease.
     Biochem Soc Trans, 39(3): 819-22. [Abstract] [Full-text]
211. Dual-task performance in Alzheimer's disease, mild cognitive impairment, and normal ageing.
     Arch Clin Neuropsychol, 26(4): 340-8. [Abstract] [Full-text]
212. Spared structural knowledge in a case of semantic dementia: implications for models of object recognition, semantic memory and structural description.
     Neuropsychologia, 49(7): 2112-20. [Abstract] [Full-text]
213. Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation.
     Biochem Biophys Res Commun, 408(4): 602-8. [Abstract] [Full-text]
214. Ameliorative effects of yokukansan on learning and memory deficits in olfactory bulbectomized mice.
     J Ethnopharmacol, 135(3): 737-46. [Abstract] [Full-text]
215. The biological activity of Humanin analogs correlates with structure stabilities in solution.
     Int J Biol Macromol, 49(1): 93-7. [Abstract] [Full-text]
216. Encapsulated native and glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease.
     Neurosci Lett, 497(1): 6-10. [Abstract] [Full-text]
217. In vivo detection of amyloid β deposition using ¹⁹F magnetic resonance imaging with a ¹⁹F-containing curcumin derivative in a mouse model of Alzheimer's disease.
     Neuroscience, 184: 120-7. [Abstract] [Full-text]
218. Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.
     Hum Mol Genet, 20(12): 2422-34. [Abstract] [Full-text]
219. Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis.
     Radiology, 259(3): 834-43. [Abstract] [Full-text]
220. Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes.
     Radiology, 259(3): 844-51. [Abstract] [Full-text]
221. Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model.
     J Biol Chem, 286(21): 18414-25. [Abstract] [Full-text]
222. Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease.
     Exp Neurol, 229(2): 440-9. [Abstract] [Full-text]
223. Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis.
     Hum Mol Genet, 20(12): 2344-55. [Abstract] [Full-text]
224. Neural substrates for writing impairments in Japanese patients with mild Alzheimer's disease: a SPECT study.
     Neuropsychologia, 49(7): 1962-8. [Abstract] [Full-text]
225. Specific deficit of colour-colour short-term memory binding in sporadic and familial Alzheimer's disease.
     Neuropsychologia, 49(7): 1943-52. [Abstract] [Full-text]
226. The impairment of emotion recognition in Huntington's disease extends to positive emotions.
     Cortex, 47(7): 880-4. [Abstract] [Full-text]
227. False item recognition in patients with Alzheimer's disease.
     Neuropsychologia, 49(7): 1897-902. [Abstract] [Full-text]
228. Visual attention deficits in Alzheimer's disease: relationship to HMPAO SPECT cortical hypoperfusion.
     Neuropsychologia, 49(7): 1741-50. [Abstract] [Full-text]
229. Systematic care for caregivers of patients with dementia: a multicenter, cluster-randomized, controlled trial.
     Am J Geriatr Psychiatry, 19(6): 521-31. [Abstract] [Full-text]
230. On the behaviour of senile dementia patients vis-à-vis the mirror: Ajuriaguerra, Strejilevitch and Tissot (1963).
     Neuropsychologia, 49(7): 1679-92. [Abstract] [Full-text]
231. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
     Acta Neuropathol, 121(6): 705-19. [Abstract] [Full-text]
232. Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine.
     Biochem Pharmacol, 81(12): 1422-34. [Abstract] [Full-text]
233. In vitro modelling of Alzheimer's disease: degeneration and cell death induced by viral delivery of amyloid and tau.
     Exp Neurol, 229(2): 226-37. [Abstract] [Full-text]
234. Multiple imputation was an efficient method for harmonizing the Mini-Mental State Examination with missing item-level data.
     J Clin Epidemiol, 64(7): 787-93. [Abstract] [Full-text]
235. Histopathological and immunohistochemical comparison of the brain of human patients with Alzheimer's disease and the brain of aged dogs with cognitive dysfunction.
     J Comp Pathol, 145(1): 45-58. [Abstract] [Full-text]
236. Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease.
     Neurologia, 26(5): 262-71. [Abstract] [Full-text]
237. Use of cognitive screening instruments in primary care: the impact of national dementia directives (NICE/SCIE, National Dementia Strategy).
     Fam Pract, 28(3): 272-6. [Abstract] [Full-text]
238. Diagnostic criteria for depression in Alzheimer disease: a study of symptom patterns using latent class analysis.
     Am J Geriatr Psychiatry, 19(6): 551-8. [Abstract] [Full-text]
239. Grief among family members of nursing home residents with advanced dementia.
     Am J Geriatr Psychiatry, 19(6): 543-50. [Abstract] [Full-text]
240. Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study.
     Am J Geriatr Psychiatry, 19(6): 532-42. [Abstract] [Full-text]
241. Does caregiver burden mediate the effects of behavioral disturbances on nursing home admission?
     Am J Geriatr Psychiatry, 19(6): 497-506. [Abstract] [Full-text]
242. Progression of language decline and cortical atrophy in subtypes of primary progressive aphasia.
     Neurology, 76(21): 1804-10. [Abstract] [Full-text]
243. The effectiveness of an exercise programme for elders with dementia in a Taiwanese day-care centre.
     Int J Nurs Pract, 17(3): 213-20. [Abstract] [Full-text]
244. Structure inducing ionic liquids-enhancement of alpha helicity in the Abeta(1-40) peptide from Alzheimer's disease.
     Chem Commun (Camb), 47(22): 6371-3. [Abstract] [Full-text]
245. Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease.
     Neurology, 76(21): 1797-803. [Abstract] [Full-text]
246. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution.
     Neurology, 76(21): 1789-96. [Abstract] [Full-text]
247. Long-term electromagnetic field treatment enhances brain mitochondrial function of both Alzheimer's transgenic mice and normal mice: a mechanism for electromagnetic field-induced cognitive benefit?
     Neuroscience, 185: 135-49. [Abstract] [Full-text]
248. Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease.
     Neuroimage, 57(1): 63-8. [Abstract] [Full-text]
249. Modeling pathogenesis of Huntington's disease with inducible neuroprogenitor cells.
     Cell Mol Neurobiol, 31(5): 737-47. [Abstract] [Full-text]
250. Bias in tensor based morphometry Stat-ROI measures may result in unrealistic power estimates.
     Neuroimage, 57(1): 1-4. [Abstract] [Full-text]
251. Algorithms, atrophy and Alzheimer's disease: cautionary tales for clinical trials.
     Neuroimage, 57(1): 15-8. [Abstract] [Full-text]
252. Socially and temporally extended end-of-life decision-making process for dementia patients.
     J Med Ethics, 37(6): 339-43. [Abstract] [Full-text]
253. Insulin receptor mutation results in insulin resistance and hyperinsulinemia but does not exacerbate Alzheimer's-like phenotypes in mice.
     Biochem Biophys Res Commun, 409(1): 34-9. [Abstract] [Full-text]
254. Urine neural thread protein measurements in Alzheimer disease.
     J Am Med Dir Assoc, 12(5): 372-6. [Abstract] [Full-text]
255. Volume reduction in subcortical regions according to severity of Alzheimer's disease.
     J Neurol, 258(6): 1013-20. [Abstract] [Full-text]
256. Stress acts cumulatively to precipitate Alzheimer's disease-like tau pathology and cognitive deficits.
     J Neurosci, 31(21): 7840-7. [Abstract] [Full-text]
257. Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy.
     J Neurosci, 31(21): 7817-30. [Abstract] [Full-text]
258. Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration.
     J Neurosci, 31(21): 7691-9. [Abstract] [Full-text]
259. Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats.
     Psychopharmacology (Berl), 215(4): 677-87. [Abstract] [Full-text]
260. Predictors of quality of life in carers for people with a progressive neurological illness: a longitudinal study.
     Qual Life Res, 20(5): 703-11. [Abstract] [Full-text]
261. Docking of the alkaloid geissospermine into acetylcholinesterase: a natural scaffold targeting the treatment of Alzheimer's disease.
     J Mol Model, 17(6): 1401-12. [Abstract] [Full-text]
262. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography.
     Brain, 134: 1647-57. [Abstract] [Full-text]
263. Effect of Shengmai-san on cognitive performance and cerebral oxidative damage in BALB/c mice.
     J Med Food, 14(6): 601-9. [Abstract] [Full-text]
264. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden.
     Brain, 134: 1635-46. [Abstract] [Full-text]
265. Accumulation of cellular prion protein within dystrophic neurites of amyloid plaques in the Alzheimer's disease brain.
     Neuropathology, 31(3): 208-14. [Abstract] [Full-text]
266. Semantic dementia with lower motor neuron disease showing FTLD-TDP type 3 pathology (sensu Mackenzie).
     Neuropathology, 31(3): 271-9. [Abstract] [Full-text]
267. Marriage and mental health: when a spouse has Alzheimer's disease.
     Arch Psychiatr Nurs, 25(3): 220-2. [Abstract] [Full-text]
268. Concept analysis of nurses' identification of pain in demented patients in a nursing home: development of a hybrid model.
     Pain Manag Nurs, 12(2): 61-9. [Abstract] [Full-text]
269. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study.
     J Nucl Med, 52(6): 848-55. [Abstract] [Full-text]
270. The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissue.
     Biomaterials, 32(23): 5489-97. [Abstract] [Full-text]
271. Plasma β-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease.
     Exp Gerontol, 46(7): 590-6. [Abstract] [Full-text]
272. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people.
     Clin Nutr, 30(3): 297-302. [Abstract] [Full-text]
273. Milestones in huntington disease.
     Mov Disord, 26(6): 1127-33. [Abstract] [Full-text]
274. Predicting survival in frontotemporal dementia with motor neuron disease.
     Neurology, 76(22): 1886-93. [Abstract] [Full-text]
275. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.
     Semin Nucl Med, 41(4): 300-4. [Abstract] [Full-text]
276. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
     Semin Nucl Med, 41(4): 283-99. [Abstract] [Full-text]
277. Voxelwise gene-wide association study (vGeneWAS): multivariate gene-based association testing in 731 elderly subjects.
     Neuroimage, 56(4): 1875-91. [Abstract] [Full-text]
278. MRI detection of tissue pathology beyond atrophy in Alzheimer's disease: introducing T2-VBM.
     Neuroimage, 56(4): 1946-53. [Abstract] [Full-text]
279. Surface-based TBM boosts power to detect disease effects on the brain: an N=804 ADNI study.
     Neuroimage, 56(4): 1993-2010. [Abstract] [Full-text]
280. A thalamo-cortico-thalamic neural mass model to study alpha rhythms in Alzheimer's disease.
     Neural Netw, 24(6): 631-45. [Abstract] [Full-text]
281. Automatic morphometry in Alzheimer's disease and mild cognitive impairment.
     Neuroimage, 56(4): 2024-37. [Abstract] [Full-text]
282. Cerebrospinal fluid/plasma quotients of essential and non-essential metals in patients with Alzheimer's disease.
     J Neural Transm, 118(6): 957-62. [Abstract] [Full-text]
283. Genetics of Alzheimer's disease: new evidences for an old hypothesis?
     Curr Opin Genet Dev, 21(3): 295-301. [Abstract] [Full-text]
284. Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease.
     J Neural Transm, 118(6): 865-75. [Abstract] [Full-text]

© 2004-2012 Dementia Research Today. All Rights Reserved.